

CSF automated cell counter, 10/16

At the AACCC show 2016

October 2016—Advanced Instruments launched its GloCyte Automated Cell Counter System. The company announced in July that it received 510(k) clearance from the Food and Drug Administration to market its GloCyte Automated Cell Counter System and GloCyte Low and High Level Controls.

The system is intended to provide a quantitative determination of red blood cells and total nucleated cells in cerebrospinal fluid collected from adult and pediatric patients. CSF is collected when physicians rely on cell counts to assist the diagnosis of infections, inflammatory processes, hemorrhage, leukemia, and malignancies that may involve the central nervous system. Low cell counts can present a challenge to standard methods.

“To date, there has not been a way to provide dependable, low cell counts,” Advanced Instruments president and CEO John Coughlin said in a statement. “We use a novel combination of fluorescence, microscopy with digital image analysis principles, highly specific reagents, and an intelligent counting algorithm to provide accurate and precise cell counts. We are very excited as this marks a major achievement in giving laboratories a new way to obtain reliable and timely CSF results.”

The GloCyte system requires 30 µL of sample per test, uses disposable test cartridges, and includes built-in quality control of Levey-Jennings charts and an audit table.

[Advanced Instruments](#), 781-320-9000